stockrow
Friday 6 November 2026
Export RNXT’s income statement to Excel — free account
RenovoRx, Inc.
RNXT Healthcare Biotechnology
RenovoRx, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.1 million, up 2,511.6% from fiscal 2024.
- Revenue
- +300.8%
- EPS
- 0.00%
- Free cash flow
- −12.7%
Quarter to September 2026, against a year earlier
1.14
0.05
−4.20%
Follow RNXT
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 |
+8 more quarters Free account |
P/S ratio |
27.08 | 23.46 | 25.80 | 26.43 | |
P/FCF ratio |
0.00 | 0.00 | 0.00 | 0.00 | |
P/Operating CF |
(29.61) | (16.17) | (10.36) | (9.83) | |
P/B ratio |
8.10 | 5.16 | 3.41 | 5.47 | |
Price to Tangible BV |
8.10 | 5.16 | 3.41 | 5.47 | |
EV/Sales |
25.07 | 21.09 | 20.72 | 24.45 | |
EV/EBITDA |
0.00 | 0.00 | 0.00 | 0.00 | |
EV/Operating CF |
(5.73) | (3.51) | (2.73) | (2.50) | |
EV/FCF |
(5.69) | (3.49) | (2.73) | (2.50) | |
Quick Ratio |
5.27 | 5.29 | 6.58 | 3.65 | |
Current Ratio |
5.65 | 5.74 | 7.15 | 4.02 | |
Net Debt/EBITDA |
3.22 | 2.83 | 3.56 | 1.99 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.23 | 0.16 | 0.10 | 0.14 | |
Operating CF/Net income |
0.70 | 0.98 | 1.05 | 1.03 | |
Capex/Depreciation |
(3.80) | (14.20) | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
116.42% | 132.01% | 218.12% | 636.97% | |
Selling, General and Administrative Expense of Revenue |
269.51% | 320.68% | 483.13% | 931.09% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
44.00% | 62.71% | 56.31% | 119.75% | |
Graham Net Nets |
0.12 | 0.18 | 0.29 | 0.18 | |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | |
Earnings Yield |
(19.87%) | (31.63%) | (32.67%) | (38.10%) | |
Free Cash Flow Yield |
(16.26%) | (25.75%) | (29.43%) | (36.98%) | |
Revenue per Share |
0.02 | 0.02 | 0.01 | 0.01 | |
Operating CF per Share |
(0.05) | (0.06) | (0.10) | (0.09) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.05) | (0.06) | (0.10) | (0.09) | |
Cash per Share |
0.22 | 0.20 | 0.33 | 0.20 | |
Shareholders Equity per Share |
0.19 | 0.19 | 0.30 | 0.15 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
0.19 | 0.19 | 0.30 | 0.15 | |
Free Cash Flow |
(2.56) | (2.94) | (3.71) | (3.02) | |
Working Capital |
9.72 | 8.93 | 11.80 | 5.93 | |
Capital Expenditures |
(0.02) | (0.07) | — | 0.00 | |
Net Current Asset Value |
8.66 | 8.32 | 11.02 | 5.22 | |
EV/EBIT |
0.00 | 0.00 | 0.00 | 0.00 | |
Capex to Sales |
0.02 | 0.08 | 0.00 | 0.00 | |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | |
| Other line items | |||||
Average Receivables |
0.39 | 0.42 | 0.26 | 0.09 | |
Average Payables |
0.90 | 0.77 | 1.04 | 0.69 | |
Average Inventory |
0.31 | — | — | — | |
Average Assets |
11.82 | 12.56 | 14.99 | 8.11 | |
Average Common Equity |
8.68 | 9.81 | 12.21 | 4.95 |
Columns are period end dates · fundamentals updated 5 Nov 2026